Q Therapeutics 10-Q 11 May 15 2015 Q1 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	3 Months Ended
	Mar. 31, 2015	11-May-15
Document and Entity Information [Abstract]
Entity Registrant Name	Q Therapeutics, Inc.
Entity Central Index Key	1366541
Document Type	10-Q
Document Period End Date	31-Mar-15
Amendment Flag	FALSE
Current Fiscal Year End Date	-19
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filer	No
Entity Current Reporting Status	Yes
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		30,826,549
Document Fiscal Period Focus	Q1
Document Fiscal Year Focus	2015

Condensed_Consolidated_Balance

Condensed Consolidated Balance Sheets (Unaudited) (USD $)	Mar. 31, 2015	Dec. 31, 2014
Current assets:
Cash	$447,225	$707,011
Receivables	1,000	4,136
Prepaid expenses and other	32,007	10,596
Total current assets	480,232	721,743
Property and equipment, net	24,060	26,568
Total assets	504,292	748,311
Current liabilities:
Accounts payable	354,447	263,728
Accrued liabilities	72,579	42,507
Accrued compensation	833,670	705,753
Derivative liabilities	7,461	32,175
Total current liabilities	1,268,157	1,044,163
Commitments (Note 6)
Stockholders' deficit:
Common stock, $0.0001 par value: 100,000,000 shares authorized; 30,826,549 and 30,477,460 shares outstanding as of March 31, 2015 and December 31, 2014, respectively	3,083	3,048
Additional paid-in capital	27,228,210	26,933,171
Accumulated deficit	-27,995,158	-27,232,071
Total stockholders' deficit	-763,865	-295,852
Total liabilities and stockholders' deficit	$504,292	$748,311

Condensed_Consolidated_Balance1

Condensed Consolidated Balance Sheets (Parenthetical) (Unaudited) (USD $)	Mar. 31, 2015	Dec. 31, 2014
Condensed Consolidated Balance Sheets [Abstract]
Common stock, par value (in Dollars per Share)	$0.00	$0.00
Common stock, shares authorized (in Shares)	100,000,000	100,000,000
Common stock, shares outstanding (in Shares)	30,826,549	30,477,460

Condensed_Consolidated_Stateme

Condensed Consolidated Statements of Operations (Unaudited) (USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Condensed Consolidated Statements of Operations [Abstract]
Revenues
Operating expenses:
General and administrative	560,328	583,862
Research and development	227,157	484,144
Total operating expenses	787,485	1,068,006
Operating loss	-787,485	-1,068,006
Other income (expense):
Gain on derivative liabilities	24,714
Interest expense	-416	-102,417
Other income, net	100	516
Total other income (expense)	24,398	-101,901
Loss before provision (benefit) for income taxes	-763,087	-1,169,907
Provision (benefit) for income taxes
Net loss	($763,087)	($1,169,907)
Weighted average number of common shares outstanding - basic and diluted (in Shares)	30,685,985	25,017,018
Net loss per common share - basic and diluted (in Dollars per Share)	($0.02)	($0.05)

Condensed_Consolidated_Stateme1

Condensed Consolidated Statements of Cash Flows (Unaudited) (USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Cash flows from operating activities:
Net loss	($763,087)	($1,169,907)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	2,508	2,318
Original debt discount		63,333
Gain on derivative liabilities	-24,714
Stock-based compensation	180,943	248,822
Common stock issued for services		24,500
Decrease (increase) in:
Receivables	3,136	5,556
Prepaid expenses and other	-21,411	-574
Increase in:
Accounts payable and accrued liabilities	120,791	355,903
Accrued compensation	127,917	127,539
Net cash used in operating activities	-373,917	-342,510
Cash flows from investing activities:
Purchase of property and equipment		-5,615
Cash flows from financing activities:
Issuance of common stock for cash		490,000
Proceeds from exercise of common stock options	3,300
Proceeds from exercise of common stock warrants	110,831
Net cash provided by financing activities	114,131	490,000
Net increase (decrease) in cash	-259,786	141,875
Cash as of beginning of the period	707,011	142,532
Cash as of end of the period	447,225	284,407
Supplemental disclosure of cash flow information:
Cash paid for interest	$416	$214

Condensed_Consolidated_Stateme2

Condensed Consolidated Statements of Cash Flows (Parenthetical) (Unaudited) (USD $)	3 Months Ended
	Mar. 31, 2014
Supplemental disclosure of noncash investing and financing activities for the three months ended March 31, 2015 and 2014:
Value of accounts payable settled through equity issuance	$2,304,030
Value of notes payable settled through equity issuance	$104,000
Conversion of stock, shares issued in settlement of accounts payable and notes payable (in Shares)	2,408,030

Organization

Organization	3 Months Ended
	Mar. 31, 2015
Organization [Abstract]
Organization	1. Organization
	Q Therapeutics, Inc. (Q Therapeutics) conducts its operations through its wholly owned subsidiary, Q Therapeutic Products, Inc. (Q Products), and Q Products’ wholly owned subsidiary, NeuroQ Research, Inc. (collectively, the Company). Q Therapeutics is a Salt Lake City, Utah-based biopharmaceutical company that is developing human cell-based therapies intended to treat degenerative diseases of the brain and spinal cord, the primary components of the central nervous system (CNS).
	These potential therapies are based on technology developed by Q Products’ co-founder Mahendra Rao, M.D., Ph.D., a leader in glial stem cell biology, during his tenure at the University of Utah and as Head of the Stem Cell Section in the Laboratory of Neuroscience at the National Institutes of Health (NIH) Institute of Aging. Dr. Rao was one of the first scientists to identify and seek patent coverage on stem cells and their progeny cells found in the CNS. After licensing Dr. Rao’s technology from the University of Utah and NIH, Q Products commenced operations in the spring of 2004 to develop cell-based therapeutics that can be sold as “off-the-shelf” pharmaceuticals.

Significant_Accounting_Policie

Significant Accounting Policies	3 Months Ended
	Mar. 31, 2015
Significant Accounting Policies [Abstract]
Significant Accounting Policies	2. Significant Accounting Policies
	The following significant accounting policies are followed by the Company in preparing its condensed consolidated financial statements:
	Basis of Presentation and Consolidation
	These unaudited interim condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and related notes included in the Company’s Form 10-K filed with the Securities and Exchange Commission (SEC) on March 31, 2015. The results of operations for the three-month period ended March 31, 2015 are not necessarily indicative of the results to be expected for the full year ending December 31, 2015. In the opinion of management, all adjustments that are necessary for a fair presentation of the financial information for the interim periods reported have been made. All such adjustments are of a normal recurring nature.
	The accompanying unaudited condensed consolidated financial statements have been prepared by management in accordance with U.S. generally accepted accounting principles (US GAAP), and include all assets and liabilities of Q Therapeutics and its wholly owned subsidiary, Q Products. All material transactions and balances have been eliminated.
	Going Concern Assumption and Liquidity
	The Company has not generated significant revenues and has been developing its products. Historically, the Company has been dependent on government grants and debt and equity raised from individual investors to sustain its operations. The Company’s continued operations will depend on its ability to raise funds through similar sources. There can be no assurance that such capital will be available on favorable terms or at all. If it is unable to raise additional capital, the Company will likely be forced to curtail desired development activities, which will delay the development of its product candidates. The Company’s products have not been approved by the U.S. Food and Drug Administration (FDA) for commercial sale; therefore, the Company has not generated revenues from commercial therapeutic product sales. As of March 31, 2015, the Company had an accumulated deficit of $27,995,158. These matters, among others, raise substantial doubt about the Company’s ability to continue as a going concern through at least March 31, 2016. No adjustments have been made to the Company’s financial statements as a result of this uncertainty.
	2014 Financing Transactions
	Between March 7 and April 14, 2014, the Company issued an aggregate of 4,420,530 units, each unit consisting of one share of the Company’s common stock and one warrant to purchase one share of the Company’s common stock for which the Company received cash consideration of $2,012,500 and settled indebtedness of $2,408,030 (2014 Financing Transactions). The warrants have an initial exercise price of $1.00 per share, are immediately exercisable, and expire in no more than four years from the date of issuance. Both the shares of common stock and the warrants issued in the 2014 Financing Transactions have a “down-round” protection provision provided to the investors in the financing. With respect to the common shares and warrants issued, with certain exceptions, if the Company subsequently issues or sells any shares of common stock or any common stock equivalents pursuant to which shares of common stock may be acquired at a price less than $1.00 per share, then the Company shall promptly issue additional shares of common stock to the investor in an amount such that the subscription price paid, when divided by the total number of shares issued will result in an actual price paid per share of common stock equal to such lower price and with respect to warrants, the warrant exercise prices shall be reduced to the lesser price at which the common stock or common stock equivalents were issued. The down-round provisions expire upon the earlier of (1) the effectiveness of a registration statement with the Securities Exchange Commission (SEC) registering the shares of common stock issued and the common shares underlying warrants issued in the 2014 Financing Transactions, or (2) one year after the issuance date. The down-round protection related to the March 7, 2014 and April 14, 2014 rounds of financing have expired.
	On June 30, 2014, the Company issued 854,363 shares of common stock and warrants to purchase 1,277,363 shares of common stock resulting from an additional tranche of financing for which the Company received cash consideration of $3,500 and a settlement of indebtedness of $850,863. The common stock and warrants have terms similar to the 2014 Financing Transactions. The remaining down-round protection will expire June 30, 2015.
	Between January 26, 2015 and February 23, 2015, 327,455 common stock warrants and 21,634 common stock options were exercised for cash proceeds of $114,131.
	Use of Estimates
	The preparation of financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosures of contingent assets and liabilities as of the dates of the financial statements and the reported amounts of revenues and expenses for the reporting periods. Accordingly, actual results could differ from those estimates. Key estimates include allowances for doubtful accounts receivable, useful lives for property and equipment, valuation allowances for net deferred income tax assets, valuation for derivative liabilities related to down-round provisions, and valuations for stock-based compensation awards. The Company bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances.
	Revenue Recognition and Grants Receivable
	The Company periodically applies for research grants, including as a sub-recipient to grants funded by government agencies through research universities. Grant revenues are recognized as associated expenses and are incurred and are billed in conjunction with the terms of the grants. The Company records its grants receivable in accordance with the provisions of the grant agreements. The Company’s grants receivable are considered past due when payment has not been received within 30 days of the invoice date, although certain institutions customarily do not pay within these terms. The amounts of the specific allowances are estimated by management based on various assumptions including the age of the individual receivable, as well as changes in payment schedules and histories. Receivable balances are charged off against the allowance for doubtful accounts when management determines the potential for recovery is remote. Recoveries of receivables previously charged off are recorded when payment is received.
	In June 2014, the Company was notified of a sub-award as part of the fourth and final year of grant funding awarded to The John Hopkins University from the National Institute of Neurological Diseases and Stroke (NINDS) of the National Institutes of Health in the amount of $677,864. As of March 31, 2015, $1,000 remains receivable from this sub-award.
	Stock-Based Compensation
	The Company calculates the estimated fair value of its stock options and warrants on the grant date using the Black-Scholes option-pricing model. The Company recognizes stock-based compensation expense as services are provided, which is generally over the vesting period of the individual equity instruments. Expense related to stock options issued in lieu of cash to non-employees for services performed are measured at the fair value of the options on the date they are earned and the related expense is recognized as services are provided.
	The volatility assumption used in the Black-Scholes option-pricing model is based on the volatility of publicly traded companies in the same industry segment as the Company. The expected lives of the options and warrants granted represent the periods of time that the options granted are expected to be outstanding. The risk free rates for periods within the contractual lives of the options and warrants are based on the U.S. Treasury securities constant maturity rate that corresponds to the expected terms in effect at the time of grant. Stock-based compensation is included in general and administrative expense in the statements of operations.
	Net Loss Per Common Share
	Basic net income or loss per common share (Basic EPS) is computed by dividing net income or loss by the weighted average number of common shares outstanding. Diluted net income or loss per common share (Diluted EPS) is computed by dividing net income or loss by the sum of the weighted average number of common shares outstanding and the dilutive potential common share equivalents then outstanding. Potential dilutive common share equivalents consist of shares issuable upon the exercise of outstanding stock options and warrants to acquire common stock.
	Due to the fact that for all periods presented the Company has incurred net losses, potential dilutive common share equivalents as of March 31, 2015 and 2014, totaling 25,761,568 and 21,437,251, respectively, are not included in the calculation of Diluted EPS because they are anti-dilutive. Therefore, basic net loss per common share is the same as diluted net loss per common share for the three months ended March 31, 2015 and 2014.
	Recent Accounting Pronouncements
	In August 2014, the Financial Accounting Standards Board (FASB) issued ASU 2014-15, Presentation of Financial Statements – Going Concern (Subtopic 310-40): Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern. ASU 2014-15 provides guidance in US GAAP about management’s responsibility to evaluate whether there is substantial doubt about an entity’s ability to continue as a going concern and to provide related disclosures. In doing so, this is intended to reduce diversity in the timing and content of disclosures. This is effective for the annual period ending after December 15, 2016, and for annual periods and interim periods thereafter. Early application is permitted. The Company is currently evaluating the potential impact of adopting this guidance on its consolidated financial statements and related disclosures.

Accrued_Compensation

Accrued Compensation	3 Months Ended
	Mar. 31, 2015
Accrued Compensation [Abstract]
Accrued Compensation	3. Accrued Compensation
	Accrued compensation consists of the following:
		March 31,		December 31,
		2015		2014
	Accrued wages	$	737,448	$	621,072
	Accrued vacation		96,222		84,681
	Total accrued compensation	$	833,670	$	705,753
	Accrued wages consist primarily of salaries and related employment taxes resulting from the decision in March 2013 by certain of the Company’s executives to defer part, if not all, of their salaries until additional funding for the Company is obtained.

Derivative_Liabilities

Derivative Liabilities	3 Months Ended
	Mar. 31, 2015
Derivative Liabilities [Abstract]
Derivative Liabilities	4. Derivative Liabilities
	In connection with the 2014 Financing Transactions, the Company recorded derivative liabilities related to down-round protection provided to stockholders in the event that the Company issues additional units, similar to those issued in the 2014 Financing Transactions, at a price below $1.00 per share. The down-round provision expires upon the earlier of the effectiveness of a registrations statement with the SEC or one year after the issuance date. With the assistance of a third-party valuation specialist, the Company valued the derivative liabilities pursuant to the accounting guidance of Accounting Standards Codification 820-10, Fair Value Measurements.
	Fair values of the down-round provision of the warrants and common stock are determined using the Monte-Carlo Simulation Model valuation technique. The Monte Carlo Simulation Model provides for dynamic assumptions regarding volatility and risk-free interest rates within the total period to expected conversion. In addition, management assessed the probabilities of future financing assumptions.
	Fair value is based on the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. In order to increase consistency and comparability in fair value measurements, US GAAP established a fair value hierarchy that prioritizes observable and unobservable inputs used to measure fair value into three broad levels, which are described below:
	Level 1	Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities.
	Level 2	Other inputs that are observable directly or indirectly, such as quoted prices for similar assets and liabilities or market corroborated inputs.
	Level 3	Unobservable inputs that are used when little or no market data is available, which require the Company to develop its own assumptions about how market participants would value the assets or liabilities.
	Determining which category an asset or liability falls within the hierarchy requires significant judgment. The Company evaluates its hierarchy disclosure each quarter. Assets and liabilities measured at fair value on a recurring basis as of March 31, 2015 are summarized as follows:
		Fair Value as of March 31, 2015
		Level 1			Level 2		Level 3		Total
	Derivative liabilities	$	—		$	—	$	7,461	$	7,461
	The following table presents the fair value reconciliation of Level 3 liabilities measured at fair value on a recurring basis during the three months ended March 31, 2015.
		Fair Value
		Measurements
		Using Significant
		Unobservable Inputs
		Derivatives
	Beginning balance, as of December 31, 2014	$	32,175
	Gain on derivative liabilities		(24,714	)
	Ending balance, as of March 31, 2015	$	7,461
	Given the nature of the derivative liabilities, the carrying amount of $7,461 as of March 31, 2015, was derived from Level 3 inputs and represent management’s best estimate of fair value.
	The valuation assumptions used in the Monte-Carlo Simulation Model for the three months ended March 31, 2015 are as follows:
	Threshold barrier	$	1
	Average down-round protection value per unit	$	0.117
	Probability of down-round offer		3	%

Stockholders_Equity_Deficit

Stockholders' Equity (Deficit)	3 Months Ended
	Mar. 31, 2015
Stockholders' Equity (Defecit) [Abstract]
Stockholders' Equity	5. Stockholders’ Equity
	Common Stock
	As of March 31, 2015, the Company is authorized to issue 100,000,000 shares of common stock, of which 30,826,549 shares are outstanding. Holders of shares of common stock are entitled to cast one vote for each share held at all stockholders’ meetings for all purposes, including the election of directors. The common stock does not have cumulative voting rights.
	Preferred Stock
	As of March 31, 2015, the Company was authorized to issue 10,000,000 shares of preferred stock; however, no shares of preferred stock have been issued to date.
	Stock Options
	The following summarizes the outstanding common stock options and related activity for the three months ended March 31, 2015:
		Number of			Weighted		Weighted		Aggregate
		Options			Average Exercise		Average		Intrinsic
					Price Per Share		Remaining Life		Value
							(Years)
	Outstanding as of December 31, 2014		8,952,927		$	0.52		7.61	$	1,601,845
	Granted		—			—		—
	Exercised		(21,634	)		0.15		—
	Forfeited		—			—		—
	Outstanding as of March 31, 2015		8,931,293			0.52		7.47		1,590,001
	Exercisable as of March 31, 2015		6,201,815			0.44		6.85		1,590,001
	For the three months ended March 31, 2015, no options were granted and 21,634 options were exercised for proceeds of $3,300.
	As of March 31, 2015, options to purchase 5,049,308 shares of common stock under the Plan were available for future grant. Stock-based compensation for the three months ended March 31, 2015 and 2014 was $180,943 and $248,822, respectively. As of March 31, 2015, the Company had $1,104,349 of unrecognized stock-based compensation expense related to non-vested awards that will be recognized over a weighted-average period of 2.78 years.
	Warrants
	In January 2015, the Company issued a warrant to purchase 50,000 shares of common stock to a business consulting firm (see Note 6). Between January 26, 2015 and February 13, 2015, 327,455 warrants were exercised for total cash proceeds of $110,831. During the three months ended March 31, 2015, 883,431 warrants had expired.
	As of March 31, 2015, 16,380,275 warrants to purchase common stock had been issued with exercise prices ranging from $1.00 to $2.75 per share and terms ranging from two to seven years. The weighted average warrant exercise price is $1.31 and the weighted average remaining life is 3.45 years.

Commitments

Commitments	3 Months Ended
	Mar. 31, 2015
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	6. Commitments
	Advisory Agreements
	In July 2013, the Company entered into a business consulting services agreement effective through December 31, 2015. Under the agreement, the Company issued an initial payment of a warrant to purchase 75,000 shares of common stock at a strike price of $1.01 per share, with a five-year life and a cashless exercise option. In January 2014 and January 2015, the Company issued two additional warrants to purchase 50,000 shares of common stock with similar terms to the initial issuance. The business consulting firm has received all the warrants earned under the agreement.

Significant_Accounting_Policie1

Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2015
Significant Accounting Policies [Abstract]
Basis of Presentation and Consolidation, Policy	Basis of Presentation and Consolidation
	These unaudited interim condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and related notes included in the Company’s Form 10-K filed with the Securities and Exchange Commission (SEC) on March 31, 2015. The results of operations for the three-month period ended March 31, 2015 are not necessarily indicative of the results to be expected for the full year ending December 31, 2015. In the opinion of management, all adjustments that are necessary for a fair presentation of the financial information for the interim periods reported have been made. All such adjustments are of a normal recurring nature.
	The accompanying unaudited condensed consolidated financial statements have been prepared by management in accordance with U.S. generally accepted accounting principles (US GAAP), and include all assets and liabilities of Q Therapeutics and its wholly owned subsidiary, Q Products. All material transactions and balances have been eliminated.
Going Concern Assumption and Liquidity, Policy	Going Concern Assumption and Liquidity
	The Company has not generated significant revenues and has been developing its products. Historically, the Company has been dependent on government grants and debt and equity raised from individual investors to sustain its operations. The Company’s continued operations will depend on its ability to raise funds through similar sources. There can be no assurance that such capital will be available on favorable terms or at all. If it is unable to raise additional capital, the Company will likely be forced to curtail desired development activities, which will delay the development of its product candidates. The Company’s products have not been approved by the U.S. Food and Drug Administration (FDA) for commercial sale; therefore, the Company has not generated revenues from commercial therapeutic product sales. As of March 31, 2015, the Company had an accumulated deficit of $27,995,158. These matters, among others, raise substantial doubt about the Company’s ability to continue as a going concern through at least March 31, 2016. No adjustments have been made to the Company’s financial statements as a result of this uncertainty.
Use of Estimates, Policy	Use of Estimates
	The preparation of financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosures of contingent assets and liabilities as of the dates of the financial statements and the reported amounts of revenues and expenses for the reporting periods. Accordingly, actual results could differ from those estimates. Key estimates include allowances for doubtful accounts receivable, useful lives for property and equipment, valuation allowances for net deferred income tax assets, valuation for derivative liabilities related to down-round provisions, and valuations for stock-based compensation awards. The Company bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances.
Revenue Recognition and Grants Receivable, Policy	Revenue Recognition and Grants Receivable
	The Company periodically applies for research grants, including as a sub-recipient to grants funded by government agencies through research universities. Grant revenues are recognized as associated expenses and are incurred and are billed in conjunction with the terms of the grants. The Company records its grants receivable in accordance with the provisions of the grant agreements. The Company’s grants receivable are considered past due when payment has not been received within 30 days of the invoice date, although certain institutions customarily do not pay within these terms. The amounts of the specific allowances are estimated by management based on various assumptions including the age of the individual receivable, as well as changes in payment schedules and histories. Receivable balances are charged off against the allowance for doubtful accounts when management determines the potential for recovery is remote. Recoveries of receivables previously charged off are recorded when payment is received.
	In June 2014, the Company was notified of a sub-award as part of the fourth and final year of grant funding awarded to The John Hopkins University from the National Institute of Neurological Diseases and Stroke (NINDS) of the National Institutes of Health in the amount of $677,864. As of March 31, 2015, $1,000 remains receivable from this sub-award.
Stock-Based Compensation, Policy	Stock-Based Compensation
	The Company calculates the estimated fair value of its stock options and warrants on the grant date using the Black-Scholes option-pricing model. The Company recognizes stock-based compensation expense as services are provided, which is generally over the vesting period of the individual equity instruments. Expense related to stock options issued in lieu of cash to non-employees for services performed are measured at the fair value of the options on the date they are earned and the related expense is recognized as services are provided.
	The volatility assumption used in the Black-Scholes option-pricing model is based on the volatility of publicly traded companies in the same industry segment as the Company. The expected lives of the options and warrants granted represent the periods of time that the options granted are expected to be outstanding. The risk free rates for periods within the contractual lives of the options and warrants are based on the U.S. Treasury securities constant maturity rate that corresponds to the expected terms in effect at the time of grant. Stock-based compensation is included in general and administrative expense in the statements of operations.
Net Loss Per Common Share, Policy	Net Loss Per Common Share
	Basic net income or loss per common share (Basic EPS) is computed by dividing net income or loss by the weighted average number of common shares outstanding. Diluted net income or loss per common share (Diluted EPS) is computed by dividing net income or loss by the sum of the weighted average number of common shares outstanding and the dilutive potential common share equivalents then outstanding. Potential dilutive common share equivalents consist of shares issuable upon the exercise of outstanding stock options and warrants to acquire common stock.
	Due to the fact that for all periods presented the Company has incurred net losses, potential dilutive common share equivalents as of March 31, 2015 and 2014, totaling 25,761,568 and 21,437,251, respectively, are not included in the calculation of Diluted EPS because they are anti-dilutive. Therefore, basic net loss per common share is the same as diluted net loss per common share for the three months ended March 31, 2015 and 2014.
Recent Accounting Pronouncements, Policy	Recent Accounting Pronouncements
	In August 2014, the Financial Accounting Standards Board (FASB) issued ASU 2014-15, Presentation of Financial Statements – Going Concern (Subtopic 310-40): Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern. ASU 2014-15 provides guidance in US GAAP about management’s responsibility to evaluate whether there is substantial doubt about an entity’s ability to continue as a going concern and to provide related disclosures. In doing so, this is intended to reduce diversity in the timing and content of disclosures. This is effective for the annual period ending after December 15, 2016, and for annual periods and interim periods thereafter. Early application is permitted. The Company is currently evaluating the potential impact of adopting this guidance on its consolidated financial statements and related disclosures.

Accrued_Compensation_Tables

Accrued Compensation (Tables)	3 Months Ended
	Mar. 31, 2015
Accrued Compensation [Abstract]
Schedule of Accrued Compensation	Accrued compensation consists of the following:
		March 31,		December 31,
		2015		2014
	Accrued wages	$	737,448	$	621,072
	Accrued vacation		96,222		84,681
	Total accrued compensation	$	833,670	$	705,753

Derivative_Liabilities_Tables

Derivative Liabilities (Tables)	3 Months Ended
	Mar. 31, 2015
Derivative Liabilities [Abstract]
Schedule of Derivative Liabilities	The Company evaluates its hierarchy disclosure each quarter. Assets and liabilities measured at fair value on a recurring basis as of March 31, 2015 are summarized as follows:
		Fair Value as of March 31, 2015
		Level 1			Level 2		Level 3		Total
	Derivative liabilities	$	—		$	—	$	7,461	$	7,461
Schedule of Derivative liability fair value unobservable input reconciliation	The following table presents the fair value reconciliation of Level 3 liabilities measured at fair value on a recurring basis during the three months ended March 31, 2015.
		Fair Value
		Measurements
		Using Significant
		Unobservable Inputs
		Derivatives
	Beginning balance, as of December 31, 2014	$	32,175
	Gain on derivative liabilities		(24,714	)
	Ending balance, as of March 31, 2015	$	7,461
Schedule of Derivative Liabilities, Valuation Assumptions	The valuation assumptions used in the Monte-Carlo Simulation Model for the three months ended March 31, 2015 are as follows:
	Threshold barrier	$	1
	Average down-round protection value per unit	$	0.117
	Probability of down-round offer		3	%

Stockholders_Equity_Deficit_Ta

Stockholders' Equity (Deficit) (Tables)	3 Months Ended
	Mar. 31, 2015
Stockholders' Equity (Defecit) [Abstract]
Summary of Outstanding Common Stock Options and Related Activity	The following summarizes the outstanding common stock options and related activity for the three months ended March 31, 2015:
		Number of			Weighted		Weighted		Aggregate
		Options			Average Exercise		Average		Intrinsic
					Price Per Share		Remaining Life		Value
							(Years)
	Outstanding as of December 31, 2014		8,952,927		$	0.52		7.61	$	1,601,845
	Granted		—			—		—
	Exercised		(21,634	)		0.15		—
	Forfeited		—			—		—
	Outstanding as of March 31, 2015		8,931,293			0.52		7.47		1,590,001
	Exercisable as of March 31, 2015		6,201,815			0.44		6.85		1,590,001

Significant_Accounting_Policie2

Significant Accounting Policies (Narrative) (Details) (USD $)	0 Months Ended	1 Months Ended						3 Months Ended
	Jun. 30, 2014	Feb. 23, 2015	Jan. 31, 2015	Jun. 30, 2014	Apr. 14, 2014	Jan. 31, 2014	Jul. 31, 2013	Mar. 31, 2015	Mar. 31, 2014	Dec. 31, 2014
Going Concern Assumption and Liquidity
Accumulated deficit								($27,995,158)		($27,232,071)
2014 Financing Transactions
Issuance of equity units for cash, $1.00 per unit, containing one share of common stock and one warrant to purchase one share of common stock (in Shares)					4,420,530
Cash proceeds for issuance of equity	3,500				2,012,500
Debt conversion, original debt amount	850,863				2,408,030
Warrants, exercise price (in Dollars per Share)					$1
Maximum warrant term (in Duration)					4 years		5 years
Floor price of prospective common stock issues below which additional shares must be issued to the investor (in Dollars per Share)					$1
Period of expiration of downround provision if earlier than the effectiveness date of a registation statement (in Duration)					1 year
Common stock issued (in Shares)	854,363
Warrants issued (in Shares)	1,277,363		50,000			50,000	75,000
Issuance of common stock on exercise of warrants (in Shares)		327,455
Options exercised (in Shares)		21,634						21,634
Proceeds from warrants and options exercised		114,131
Revenue Recognition and Grants Receivable
Period after which grants receivable are considered past due								30 days
Grant revenue invoiced under sub-award				677,864
Grants receivable, sub-award								$1,000
Net Loss Per Common Share
Anti-dilutive common share equivalents excluded from calculation of diluted earnings per share (in Shares)								25,761,568	21,437,251

Accrued_Compensation_Schedule_

Accrued Compensation (Schedule of Accrued Compensation) (Details) (USD $)	Mar. 31, 2015	Dec. 31, 2014
Accrued Compensation [Abstract]
Accrued wages	$737,448	$621,072
Accrued vacation	96,222	84,681
Total accrued compensation	$833,670	$705,753

Derivative_Liabilities_Narrati

Derivative Liabilities (Narrative) (Details) (USD $)	Mar. 31, 2015
Derivative Liabilities [Abstract]
Stock price floor for new share sales, below which additional shares of common stock must be issued to warrant investors (in Dollars per Share)	$1
Derivative liabilities	$7,461

Derivative_Liabilities_Schedul

Derivative Liabilities (Schedule of Assets and Liabilities Measured at Fair Value on a Recurring Basis) (Details) (USD $)	Mar. 31, 2015	Dec. 31, 2014
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Derivative liabilities	$7,461
Fair Value Inputs Level 1 [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Derivative liabilities
Fair Value Inputs Level 2 [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Derivative liabilities
Fair Value Inputs Level 3 [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Derivative liabilities	$7,461	$32,175

Derivative_Liabilities_Schedul1

Derivative Liabilities (Schedule of Level 3 Liabilities, Fair Value Reconciliation) (Details) (USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Gain on derivative liabilities	($24,714)
Ending balance, as of March 31, 2015	7,461
Fair Value Inputs Level 3 [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Beginning balance, as of December 31, 2014	32,175
Gain on derivative liabilities	-24,714
Ending balance, as of March 31, 2015	$7,461

Derivative_Liabilities_Schedul2

Derivative Liabilities (Schedule of Valuation Assumptions Used In The Monte Carlo Simulation Model) (Details) (USD $)	3 Months Ended
	Mar. 31, 2015
Derivative Liability Fair Value Assumptions and Methodology Used in Monte Carlo Model
Threshold barrier	$1
Average, down-round protection value per unit	$0.12
Probability of down-round offer	3.00%

Stockholders_Equity_Deficit_Na

Stockholders' Equity (Deficit) (Narrative) (Details) (USD $)	0 Months Ended	1 Months Ended						3 Months Ended
	Jun. 30, 2014	Feb. 13, 2015	Feb. 23, 2015	Jan. 31, 2015	Apr. 14, 2014	Jan. 31, 2014	Jul. 31, 2013	Mar. 31, 2015	Mar. 31, 2014	Dec. 31, 2014
Common Stock
Common stock, shares authorized (in Shares)								100,000,000		100,000,000
Common stock, shares outstanding (in Shares)								30,826,549		30,477,460
Preferred Stock
Preferred stock, shares authorized (in Shares)								10,000,000
Preferred stock, shares issued (in Shares)								0
Stock Options
Number of options granted (in Shares)
Options exercised (in Shares)			21,634					21,634
Proceeds from exercise of common stock options								$3,300
Common shares available for future grant (in Shares)								5,049,308
Stock-based compensation								180,943	248,822
Unrecognized stock-based compensation expense related to non-vested awards								1,104,349
Unrecognized stock-based compensation expense related to non-vested awards, weighted-average period of recognition (in Duration)								2 years 9 months 11 days
Warrants
Common stock issuable under each warrant issued (in Shares)	1,277,363			50,000		50,000	75,000
Warrants exercised (in Shares)		327,455
Proceeds from warrants exercised		$110,831
Warrants expired (in Shares)								883,431
Common stock issuable on excercise of warrants (in Shares)								16,380,275
Exercise price of warrants (in Dollars per Unit)							$1.01
Maximum warrant term (in Duration)					4 years		5 years
Weighted average exercise price of warrants (in Dollars per Unit)								$1.31
Warrants, weighted average remaining life (in Duration)								3 years 5 months 12 days
Minimum [Member]
Warrants
Warrants, outstanding (in Shares)								1
Maximum warrant term (in Duration)								2 years
Maximum [Member]
Warrants
Warrants, outstanding (in Shares)								2.75
Maximum warrant term (in Duration)								7 years

Stockholders_Equity_Deficit_Su

Stockholders' Equity (Deficit) (Summary of Outstanding Common Stock Options and Related Activity) (Details) (USD $)	1 Months Ended	3 Months Ended	12 Months Ended
	Feb. 23, 2015	Mar. 31, 2015	Dec. 31, 2014
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of Options Outstanding, beginning balance (in Shares)		8,952,927
Number of Options, Granted (in Shares)
Number of Options, Exercised (in Shares)	-21,634	-21,634
Number of Options, Forfeited (in Shares)
Number of Options Outstanding, ending balance (in Shares)		8,931,293	8,952,927
Number of Options, Exercisable, ending balance (in Shares)		6,201,815
Weighted Average Exercise Price Per Share, Outstanding, beginning balance (in Dollars per Share)		$0.52
Weighted Average Exercise Price Per Share, Granted (in Dollars per Share)
Weighted Average Exercise Price Per Share, Exercised (in Dollars per Share)		$0.15
Weighted Average Exercise Price Per Share, Forfeited (in Dollars per Share)
Weighted Average Exercise Price Per Share, Outstanding, ending balance (in Dollars per Share)		$0.52	$0.52
Weighted Average Exercise Price Per Share, Exercisable, ending balance (in Dollars per Share)		$0.44
Weighted Average Remaining Life, options outstanding (Years) (in Duration)		7 years 5 months 19 days	7 years 7 months 10 days
Weighted Average Remaining Life, options granted (Years) (in Duration)
Weighted Average Remaining Life, options exercisable (Years) (in Duration)		6 years 10 months 6 days
Outstanding stock options, aggregate intrinsic value		$1,590,001	$1,601,845
Stock options exercisable, aggregate intrinsic value		$1,590,001

Commitments_Narrative_Details

Commitments (Narrative) (Details) (USD $)	0 Months Ended	1 Months Ended				13 Months Ended
	Jun. 30, 2014	Jan. 31, 2015	Apr. 14, 2014	Jan. 31, 2014	Jul. 31, 2013	Jan. 31, 2015
Commitments and Contingencies Disclosure [Abstract]
Common stock issuable under each warrant issued (in Shares)	1,277,363	50,000		50,000	75,000
Exercise price of warrants (in Dollars per Unit)					$1.01
Warrant term (in Duration)			4 years		5 years
Number of warrants issued (in Warrants)						2